Science and Technologies

Areas of Partnering Interest

Discovery Platform Lines

• Computational methods for predictive toxicology
• Novel chemical space—non-rule of five compliant molecules
• Flow chemistry
• Stem Cell technologies for use either as research tools or to enable cell-based therapies
• Genetically modified mice: Knock-outs/ins, phenotyping, gene targeting
• Functional cell-based assays: Panels of fully characterized pharmacological functional assays
• Methods in preclinical Magnetic Resonance Imaging (MRI), PET, CT, Ultrasound, and Optical
• Alternate indications for existing drugs based on human clinical data
• Structural Biology, biophysics, and mass spectrometry of G-protein-coupled receptors and ion channels
• Integrated Chemistry/ Biology, PDM outsourcing
• Improvements in synthetic chemistry productivity: Real-time reaction monitoring, purification, flow analysis

Drug Safety Research & Development (R&D)

• Safety Biomarker Technologies
• Platforms, Multiplex, Analytical approaches, Reagants
• Target Organ Toxicity—mechanisms and biomarkers
• Liver Injury
• Hypersensitivity
• Cardiovascular safety
• Nephrotoxicity
• Skeletal and Cardiac muscle toxicity
• Biotherapeutics
• Immunogenicity and other safety-relevant assays
• Automation
• Pathology Automation
• Pre-CAN Confidence in Safety (CIS)
• Improved in vitro model systems
• Structure-Toxicology Approaches
• Deeper Knowledge of Targets and Pathways
• Knockdown technologies
• Animal model
• Increased throughput for target localization

Pharmacokinetics, Dynamics and Metabolism

• Biotransformation
• Structure elucidation of metabolites
• In vitro metabolism, enzymology and drug interactions, in vitro and in vivo drug transport
• Bioanalytics
• Lab automation, high throughput platforms (LC/MS/MS), IT solutions for enhanced productivity
• Miniaturization, lab-on-a-chip, sensors, ligand binding assays for macromolecules
• In Silico/High Throughput (HT) Screening
• In silico models of key PDM endpoints to support compound design and progressions
• HT screening of key ADME endpoints to support compound progression and decision making
• Pharmacokinetics (PK)/Pharmacodynamics (PD)
• Mathematical modeling of PK and PD
• Model-based translation of preclinical biomarkers of efficacy, pharmacology and safety
• Biologics & Biomarkers
• Biotherapeutics beyond Antibodies and Vaccines
• Identification, development of soluble biomarkers from preclinical to early clinical

• Submit your idea



• Back to Areas of Interest